PregLem Weighs Financing Options Well Ahead Of Uterine Fibroid Drug Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Esmya, an oral therapy being developed for symptomatic uterine fibroids, showed non-inferiority to GnRH agonists in a Phase III study.